Port Capital LLC Takes Position in Thermo Fisher Scientific Inc. $TMO

Port Capital LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, Holdings Channel reports. The institutional investor purchased 1,182 shares of the medical research company’s stock, valued at approximately $593,000.

Several other large investors have also recently made changes to their positions in the business. Legacy Wealth Managment LLC ID boosted its holdings in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the last quarter. Kilter Group LLC bought a new stake in Thermo Fisher Scientific in the second quarter worth about $25,000. Allied Private Wealth LLC purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $26,000. High Note Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the last quarter. Finally, Swiss RE Ltd. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on TMO shares. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Piper Sandler boosted their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price for the company. Finally, HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price target for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $634.48 on Thursday. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $647.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market capitalization of $234.60 billion, a price-to-earnings ratio of 34.13, a PEG ratio of 2.56 and a beta of 0.85. The company’s fifty day moving average price is $552.22 and its 200-day moving average price is $510.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same period in the previous year, the business earned $4.28 earnings per share. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.